Other Clinical Trial - Compare Early With Deferred Invasive Strategy for

Status Not yet recruiting

Clinical Trial Summary

The primary objective of the trial is to compare the efficacy of early with deferred invasive strategy for patients with ST-segment elevation myocardial infarction (STEMI) within 24-48h of symptom onset.

Clinical Trial Description

At present, timely primary percutaneous coronary intervention (PCI) is the preferred strategy for STEMI patients within 24h of symptom onset. In stable STEMI patients presenting 12 to 48 hours from symptom onset, BRAVE-2 Trial (n = 365) showed improved myocardial salvage and 4-year survival in patients treated with primary PCI compared with conservative treatment alone. However, data is scarce about the reperfusion strategy focusing on STEMI patients within 24-48h of symptom onset.

To our knowledge, due to the long onset time and insufficient antiplatelet/anticoagulant treatment, infarct-related artery in STEMI patients beyond 24h of symptom onset frequently suffer from severer thrombus burden. In this situation, the risk of no-reflow in primary PCI is high. Meanwhile, myocardial coagulative necrosis would be fully developed during 24-72h from symptom onset, the risk of perioperative cardiac rupture may also rise. These bring some doubts about the benefits of early invasive strategy for STEMI patients within 24-48h of symptom onset. Further investigations are warranted to explore the best timing of invasive strategy for STEMI patients within 24-48h of symptom onset.

Given that no randomized clinical trial is designed especially for STEMI patients within 24-48h of symptom onset, and limited data is available to compare early with deferred invasive strategy for the subgroup of STEMI patients, investigators plan to perform a controlled, randomized trial to compare the efficacy of early with deferred invasive strategy for STEMI patients within 24-48h of symptom onset. ;

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
ST-segment Elevation Myocardial Infarction (STEMI)

Clinical Trial Details

NCT number	NCT04575012
Study type	Interventional
Source	Shanghai Zhongshan Hospital
Contact	Xin Zhong, M.D.
Phone	+86 13585678706
Email	zhong.xin@zs-hospital.sh.cn
Status	Not yet recruiting
Phase	N/A
Start date	December 1, 2020
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04962178` - Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset	N/A
Not yet recruiting	`NCT04549766` - Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
Not yet recruiting	`NCT05511831` - The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI	Phase 4
Completed	`NCT05649696` - Prolonged Clinical Follow-up of OPTIMA-5	Phase 4
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT01144819` - Platelet Inhibition in the Acute Phase of STEMI	N/A
Recruiting	`NCT03539133` - Systemic Organ Communication in STEMI
Completed	`NCT01642667` - Pharmacoinvasive Therapy With Prourokinase	Phase 2/Phase 3
Completed	`NCT04131816` - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program	N/A
Recruiting	`NCT03768453` - EARLY-MYO-CMR Registry
Completed	`NCT04942977` - Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy	N/A
Recruiting	`NCT04912518` - Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction	N/A
Completed	`NCT04996901` - The Chinese STEMI PPCI Registry (CSPR)
Recruiting	`NCT05892042` - Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction	N/A
Completed	`NCT02197117` - Effect of Remote Ischemic Conditioning in Heart Attack Patients	N/A
Completed	`NCT02733341` - The Effect of IV Cangrelor and Oral Ticagrelor Study	Phase 4
Not yet recruiting	`NCT04110691` - Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
Recruiting	`NCT05510661` - Use of Export in Primary Percutaneous Coronary Intervention	N/A
Recruiting	`NCT05709626` - PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction	Phase 4
Recruiting	`NCT05046483` - Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Compare Early With Deferred Invasive Strategy for STEMI Presenting 24-48 Hours From Symptom Onset

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms